Ignite Creation Date:
2024-05-06 @ 7:42 PM
Last Modification Date:
2024-10-26 @ 3:12 PM
Study NCT ID:
NCT06100796
Status:
RECRUITING
Last Update Posted:
2023-10-25
First Post:
2023-10-14
Brief Title:
Effect of DM on Outcomes and Response Rate in Patients With Advanced NSCLC on ICI
Sponsor:
Assiut University
Organization:
Assiut University
Study Overview
Official Title:
Effect of Diabetes Mellitus on Outcomes and Response Rate in Patients With Advanced NSCLC on Immunotherapy
Status:
RECRUITING
Status Verified Date:
2023-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
NSCLC
Brief Summary:
Retrospectively investigating the effect of DM on response rate and outcomes during immunotherapy treatment in patients with NSCLC in the last 5 years
Detailed Description:
Lung cancer continues to be the most common cause of cancer-related death worldwide for both males and females despite the identification of clinically-actionable driver mutations in genomic subgroups of patients Non-small cell lung cancer NSCLC is the most common histological diagnosis for 85 of lung cancer patients Immune checkpoint inhibitors ICI has significantly altered the prognosis for patients with advanced non-small cell lung cancer mNSCLC as it has been shown to have distinct and long-lasting impacts on survival in first and second line treatment As a result immunotherapy has emerged as the backbone of care for people with NSCLC Although some patients benefit considerably from ICI not all patients do A comprehensive research effort exists to identify and characterize variables that could predict or boost the response to ICI
At the same time diabetes mellitus DM is becoming more prevalent globally and lung cancer patients frequently suffer from a variety of comorbidities including DM However its effect on treatment outcomes is still unclear particularly in the era of immunotherapy
At the same time diabetes mellitus DM is becoming more prevalent globally and lung cancer patients frequently suffer from a variety of comorbidities including DM However its effect on treatment outcomes is still unclear particularly in the era of immunotherapy
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None